Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

KA

Kineta Inc

Sep 12 • 04:00PM ET

0.7500

Dollar change -0.0224
Percentage change -2.90	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.81	Insider Own	34.43%	Shs Outstand	10.40M	Perf Week	13.64%
Market Cap	9.20M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	8.04M	Perf Month	23.97%
Income	-20.88M	PEG	-	EPS next Q	-0.42	Inst Own	6.00%	Short Float	0.35%	Perf Quarter	56.38%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-10.79%	Short Ratio	0.04	Perf Half Y	21.89%
Book/sh	-0.66	P/B	-	EPS next Y	-	ROA	-220.89%	Short Interest	0.03M	Perf Year	-63.05%
Cash/sh	0.08	P/C	9.48	EPS next 5Y	-	ROE	-	52W Range	0.33 - 5.39	Perf YTD	-79.34%
Dividend Est.	-	P/FCF	-	EPS past 5Y	64.46%	ROI	-	52W High	-86.09%	Beta	0.46
Dividend TTM	-	Quick Ratio	0.14	Sales past 5Y	49.19%	Gross Margin	92.70%	52W Low	124.62%	ATR (14)	0.07
Dividend Ex-Date	Dec 19, 2022	Current Ratio	0.14	EPS Y/Y TTM	91.33%	Oper. Margin	0.00%	RSI (14)	63.18	Volatility	10.11% 10.62%
Employees	11	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	13.50
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-613.92%	Payout	-	Rel Volume	0.04	Prev Close	0.77
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-100.00%	Earnings	May 15 AMC	Avg Volume	699.82K	Price	0.75
SMA20	15.68%	SMA50	15.41%	SMA200	-47.35%	Trades		Volume	27,871	Change	-2.90%

Aug-20-24 06:33AM	After 5 months of financial woes, Kineta restarts recruitment in Phase I/II trial (Clinical Trials Arena) +9.19%
Aug-19-24 09:00AM	TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer (PR Newswire) +13.26%
09:00AM	Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer (GlobeNewswire)
Jul-08-24 07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) +8.77%
06:30AM	TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint Inhibitor (PR Newswire)
06:30AM	Loading…
06:30AM	Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences (GlobeNewswire)
Jun-18-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) -7.50%
Jun-17-24 07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) +5.99%
May-29-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
May-15-24 09:54PM	KA Stock Earnings: Kineta Misses EPS for Q1 2024 (InvestorPlace) -8.04%
04:15PM	Kineta: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities (GlobeNewswire)
Apr-08-24 04:01PM	Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial (GlobeNewswire) -20.37%
Mar-21-24 10:54PM	KA Stock Earnings: Kineta Beats EPS for Q4 2023 (InvestorPlace) +9.76%
04:02PM	Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Loading…
Mar-12-24 08:00AM	KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported (GlobeNewswire) -9.29%
Feb-29-24 09:36AM	After saving Yumanity's assets, Kineta faces shutdown as private placement fails to show up (FierceBiotech.com) -63.72%
08:30AM	Kineta Announces Restructuring and Exploration of Strategic Alternatives (GlobeNewswire)
Feb-22-24 08:30AM	Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium (GlobeNewswire)
Feb-14-24 08:30AM	Kineta to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-07-24 08:30AM	Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series (GlobeNewswire)
Jan-17-24 08:30AM	Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors (GlobeNewswire)
Jan-04-24 08:30AM	Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event (GlobeNewswire) -8.00%
Dec-15-23 08:35AM	Life Science Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
Dec-13-23 08:30AM	Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer (GlobeNewswire)
Dec-12-23 01:02PM	Life Science Investor Forum Agenda Announced for December 14th, 2023 (GlobeNewswire)
09:24AM	Kineta to Present at the Life Sciences Investor Forum December 14th (GlobeNewswire)
Nov-28-23 08:30AM	Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023 (GlobeNewswire) +5.81%
Nov-09-23 08:30AM	Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit (GlobeNewswire)
Nov-06-23 08:30AM	Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire) +5.74%
04:07PM	Loading…
Nov-03-23 04:07PM	Kineta: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
04:00PM	Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire)
Oct-17-23 08:30AM	Kineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA (pembrolizumab) in Patients with Advanced Solid Tumors (GlobeNewswire)
Oct-12-23 10:19AM	Kineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted for Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023 (GlobeNewswire)
07:20AM	KA: Autumn Activity (Zacks)
Oct-09-23 12:10PM	Kineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023 (GlobeNewswire) +6.41%
Oct-05-23 04:09PM	Kineta, Inc. Announces Closing of $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (GlobeNewswire) -5.04% -5.45%
Oct-04-23 08:30AM	Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy (GlobeNewswire) -12.03%
08:00AM	Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (GlobeNewswire)
Oct-03-23 08:30AM	Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial (GlobeNewswire) -12.03%
Sep-28-23 09:30AM	Kineta Announces Participation at October Investor Conferences (GlobeNewswire) +13.87%
Sep-25-23 09:30AM	Kineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy (GlobeNewswire) +8.26%
Sep-18-23 09:30AM	Kineta Announces New Research Agreement to Evaluate VISTA Biomarker Expression (GlobeNewswire) +14.51%
Sep-16-23 09:00PM	Insider Buying: Thierry Guillaudeux Acquires 10,000 Shares of Kineta Inc (GuruFocus.com)
Aug-31-23 09:30AM	Kineta to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-16-23 06:44AM	KA: Second Quarter Results (Zacks)
Aug-11-23 04:07PM	Kineta: Q2 Earnings Snapshot (AP Finance) +6.51%
04:01PM	Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-04-23 06:23AM	Force Webinar: Kineta, Ushering In A New Era Of Immunotherapy (Zacks Small Cap Research) -5.26%
Aug-03-23 08:03AM	Force Webinar: Kineta, Ushering In A New Era Of Immunotherapy (Zacks Small Cap Research) +8.57%
Jul-26-23 01:30PM	Northland Capital Markets Institutional Investor Conference (ACCESSWIRE)
Jun-29-23 06:30AM	Kineta to Receive $5 Million Milestone Payment from Merck (GlobeNewswire) +16.74%
Jun-28-23 06:30AM	Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla (GlobeNewswire) -8.84%
Jun-20-23 05:50AM	KA: A VISTA to a Cure (Zacks Small Cap Research)
May-24-23 06:30AM	Kineta Set to Join Russell Microcap® Index (GlobeNewswire)
May-23-23 06:30AM	Kineta to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 05:39PM	Kineta: Q1 Earnings Snapshot (AP Finance) -5.95%
05:20PM	Kineta Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-24-23 04:01PM	Kineta, Inc. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (GlobeNewswire)
Apr-20-23 08:38AM	Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (GlobeNewswire) -14.74%
Apr-17-23 06:30AM	Kineta Unveils New VISTA Biomarker Data and KVA12123 Phase 1/2 Clinical Trial Update at AACR Annual Meeting 2023 (GlobeNewswire) +34.38%
Apr-12-23 06:30AM	Kineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123 for Advanced Solid Tumors (GlobeNewswire) +8.25%
Apr-03-23 06:30AM	Kineta to Present at 22nd Annual Needham Healthcare Conference (GlobeNewswire) +5.74%
Mar-31-23 04:01PM	Kineta Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-22-23 06:30AM	Kineta to Present VISTA Biomarker Data at AACR Annual Meeting 2023 (GlobeNewswire)
Mar-08-23 06:30AM	Kineta to Present at the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Mar-06-23 06:30AM	Kineta to Host Key Opinion Leader Event on KVA12123: VISTA as an Immuno-Oncology Target (GlobeNewswire)
Mar-01-23 06:30AM	Kineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts to its Scientific Advisory Board (GlobeNewswire)

Kineta, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies for cancer patients. Its pipeline includes immuno-suppression: aVISTA mAb and exhausted T-cells: aCD27 agonist mAb. The company was founded by Shawn P. Iadonato and Charles L. Magness in 2008 and is headquartered in Mercer Island, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bartoszek Raymond J.	Director	Dec 05 '23	Buy	4.50	1,000	4,500	16,956	Dec 06 06:21 PM
Bartoszek Raymond J.	Director	Dec 04 '23	Buy	4.33	1,000	4,325	15,956	Dec 06 06:21 PM
Bartoszek Raymond J.	Director	Dec 06 '23	Buy	4.50	250	1,125	17,206	Dec 06 06:21 PM
PHILIPS CRAIG W.	President	Nov 28 '23	Buy	3.27	3,000	9,812	60,811	Nov 30 05:27 PM
Iadonato Shawn	Chief Executive Officer	Nov 29 '23	Buy	3.51	4,100	14,403	675,230	Nov 30 05:21 PM
Iadonato Shawn	Chief Executive Officer	Nov 28 '23	Buy	3.33	900	2,995	671,130	Nov 30 05:21 PM
Foote Marion R	Director	Oct 11 '23	Option Exercise	0.14	4,443	622	143,204	Oct 12 04:25 PM
PHILIPS CRAIG W.	President	Sep 21 '23	Buy	2.40	2,900	6,970	57,811	Sep 21 04:58 PM
PHILIPS CRAIG W.	President	Sep 20 '23	Buy	2.54	600	1,525	54,911	Sep 21 04:58 PM
Kenny Pauline	General Counsel & Secretary	Sep 20 '23	Buy	2.58	1,500	3,870	18,448	Sep 21 04:57 PM
Iadonato Shawn	Chief Executive Officer	Sep 20 '23	Buy	2.50	10,000	25,042	670,230	Sep 21 04:57 PM
Bartoszek Raymond J.	Director	Sep 19 '23	Buy	2.37	2,000	4,745	14,956	Sep 21 04:56 PM
Baker Keith	Chief Financial Officer	Sep 18 '23	Buy	2.13	5,000	10,672	16,880	Sep 19 05:03 PM
Bartoszek Raymond J.	Director	Sep 18 '23	Buy	2.08	2,500	5,200	12,956	Sep 19 05:02 PM
Bartoszek Raymond J.	Director	Sep 15 '23	Buy	2.18	500	1,090	10,456	Sep 19 05:02 PM
Guillaudeux Thierry	Chief Scientific Officer	Sep 14 '23	Buy	2.00	10,000	20,000	21,696	Sep 15 06:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KA

Kineta Inc

Upgrade your FINVIZ experience